Causes and prevalence of visual impairment among adults in the United States - PubMed (original) (raw)
Comparative Study
. 2004 Apr;122(4):477-85.
doi: 10.1001/archopht.122.4.477.
Affiliations
- PMID: 15078664
- DOI: 10.1001/archopht.122.4.477
Comparative Study
Causes and prevalence of visual impairment among adults in the United States
Nathan Congdon et al. Arch Ophthalmol. 2004 Apr.
Abstract
Objectives: To estimate the cause-specific prevalence and distribution of blindness and low vision in the United States by age, race/ethnicity, and gender, and to estimate the change in these prevalence figures over the next 20 years.
Methods: Summary prevalence estimates of blindness (both according to the US definition of < or =6/60 [< or =20/200] best-corrected visual acuity in the better-seeing eye and the World Health Organization standard of < 6/120 [< 20/400]) and low vision (< 6/12 [< 20/40] best-corrected vision in the better-seeing eye) were prepared separately for black, Hispanic, and white persons in 5-year age intervals starting at 40 years. The estimated prevalences were based on recent population-based studies in the United States, Australia, and Europe. These estimates were applied to 2000 US Census data, and to projected US population figures for 2020, to estimate the number of Americans with visual impairment. Cause-specific prevalences of blindness and low vision were also estimated for the different racial/ethnic groups.
Results: Based on demographics from the 2000 US Census, an estimated 937 000 (0.78%) Americans older than 40 years were blind (US definition). An additional 2.4 million Americans (1.98%) had low vision. The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness. Cataract was the leading cause of low vision, responsible for approximately 50% of bilateral vision worse than 6/12 (20/40) among white, black, and Hispanic persons. The number of blind persons in the US is projected to increase by 70% to 1.6 million by 2020, with a similar rise projected for low vision.
Conclusions: Blindness or low vision affects approximately 1 in 28 Americans older than 40 years. The specific causes of visual impairment, and especially blindness, vary greatly by race/ethnicity. The prevalence of visual disabilities will increase markedly during the next 20 years, owing largely to the aging of the US population.
Similar articles
- Prevalence and Causes of Visual Impairment in a Chinese Adult Population: The Taizhou Eye Study.
Tang Y, Wang X, Wang J, Huang W, Gao Y, Luo Y, Lu Y. Tang Y, et al. Ophthalmology. 2015 Jul;122(7):1480-8. doi: 10.1016/j.ophtha.2015.03.022. Epub 2015 May 16. Ophthalmology. 2015. PMID: 25986897 - Prevalence and causes of visual impairment in The Barbados Eye Study.
Hyman L, Wu SY, Connell AM, Schachat A, Nemesure B, Hennis A, Leske MC. Hyman L, et al. Ophthalmology. 2001 Oct;108(10):1751-6. doi: 10.1016/s0161-6420(01)00590-5. Ophthalmology. 2001. PMID: 11581045 - Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study.
Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, Jonas JB. Xu L, et al. Ophthalmology. 2006 Jul;113(7):1134.e1-11. doi: 10.1016/j.ophtha.2006.01.035. Epub 2006 May 2. Ophthalmology. 2006. PMID: 16647133 - Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Flaxman SR, et al. Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11. Lancet Glob Health. 2017. PMID: 29032195 Review. - Causes of blindness and visual impairment in Latin America.
Furtado JM, Lansingh VC, Carter MJ, Milanese MF, Peña BN, Ghersi HA, Bote PL, Nano ME, Silva JC. Furtado JM, et al. Surv Ophthalmol. 2012 Mar-Apr;57(2):149-77. doi: 10.1016/j.survophthal.2011.07.002. Epub 2011 Dec 2. Surv Ophthalmol. 2012. PMID: 22137039 Review.
Cited by
- The unfolded protein response and diabetic retinopathy.
Ma JH, Wang JJ, Zhang SX. Ma JH, et al. J Diabetes Res. 2014;2014:160140. doi: 10.1155/2014/160140. Epub 2014 Oct 29. J Diabetes Res. 2014. PMID: 25530974 Free PMC article. Review. - Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea.
Lee YJ, Kang S, Won JY, Roh YJ, Ra H, Lee MY, Park SP, Jee DH. Lee YJ, et al. PLoS One. 2024 Oct 3;19(10):e0310381. doi: 10.1371/journal.pone.0310381. eCollection 2024. PLoS One. 2024. PMID: 39361587 Free PMC article. - Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.
Rowe LW, Ciulla TA. Rowe LW, et al. Genes (Basel). 2024 Jun 1;15(6):720. doi: 10.3390/genes15060720. Genes (Basel). 2024. PMID: 38927656 Free PMC article. Review. - Immunological Aspects of Age-Related Macular Degeneration.
Allingham MJ, Loksztejn A, Cousins SW, Mettu PS. Allingham MJ, et al. Adv Exp Med Biol. 2021;1256:143-189. doi: 10.1007/978-3-030-66014-7_6. Adv Exp Med Biol. 2021. PMID: 33848001 - Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning.
Chandra RS, Ying GS. Chandra RS, et al. Ophthalmol Retina. 2024 May;8(5):419-430. doi: 10.1016/j.oret.2023.11.010. Epub 2023 Nov 24. Ophthalmol Retina. 2024. PMID: 38008218 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical